Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$1,060.86 USD

1,060.86
452,590

+5.29 (0.50%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $1,065.30 +4.44 (0.42%) 9:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Arpita Dutt headshot

Regeneron vs. Alexion: Which Stock is a Better Pick Post Q2 Earnings?

Biotech companies, Regeneron (REGN) and Alexion, both topped estimates in Q2 and raised their outlook. But, which stock is better-positioned for the second half of the year?

    Arpita Dutt headshot

    Forget Teva (TEVA), Buy These 4 Drug Stocks Instead

    With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.

      Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus

      Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.

        Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up

        Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.

          Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat

          Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.

            Arpita Dutt headshot

            Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data

            Regeneron (REGN) and several other biotech companies reported Q2 earnings while FibroGen hit a 52-week high on promising idiopathic pulmonary fibrosis (IPF) data.

              The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP

              The Zacks Analyst Blog Highlights: ExxonMobil, MasterCard, Shell, Regeneron and BP

                Mark Vickery headshot

                Top Research Reports for ExxonMobil, MasterCard & Shell

                Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), MasterCard (MA), and Shell (RDS.A).

                  Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View

                  Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.

                    Ekta Bagri headshot

                    Regeneron (REGN) Q2 Earnings Beat Estimates

                    Regeneron Pharmaceuticals (REGN) reported second quarter results, beating estimates on both counts

                      What's in the Cards for Adverum (ADVM) this Earnings Season?

                      Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

                        Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised

                        Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.

                          Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura

                          Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.

                            Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?

                            Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release second-quarter 2017 results on Aug 3 and we expect focus on Eylea's performance.

                              Tirthankar Chakraborty headshot

                              5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

                              Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

                                Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff

                                Both stocks carry a Zacks Rank #2 (Buy).

                                  Apple's Tim Cook earns $145M in 2016, Tops S&P 500 CEOs

                                  Apple Inc.'s (AAPL) Chief Executive Officer (CEO) Tim Cook has been declared the highest-paid CEO in the U.S., per a Bloomberg's report of take-home pay for the top 25 S&P 500 CEOs.

                                    BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase

                                    BioMarin Pharmaceutical Inc. (BMRN) announced that it has filed a biologics license application (BLA) with the FDA for its pipeline candidate, pegvaliase for phenylketonuria (PKU).

                                      Roche (RHHBY) Launches Cobas Test for Bacterial Infections

                                      Roche Holdings AG (RHHBY) launched CE-IVD, the cobas MRSA/SA nucleic acid test be used on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant MRSA and SA at the point of care.

                                        Marinus' (MRNS) Ganaxolone Gets Orphan Drug Status in US

                                        Marinus Pharmaceuticals, Inc. (MRNS) announced that the FDA has granted orphan drug designation to its key candidate, ganaxolone, for the treatment of adult and pediatric patients with CDKL5 disorder.

                                          Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

                                          Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

                                            Acorda Files NDA for Parkinson's Disease Candidate Inbrija

                                            Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.

                                              Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group

                                              Zacks.com featured highlights: Principal Financial Group, Regeneron Pharmaceuticals, Zebra Technologies, United Technologies and T. Rowe Price Group

                                                Sarepta Appoints Ex-Allergan Executive as CEO and President

                                                Sarepta Therapeutics, Inc. (SRPT) announced the appointment of Douglas S. Ingram as the new chief executive officer (CEO).

                                                  Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy

                                                  The pharma and biotech industry has been blessed with good health in the first half of the year.